Recent

% | $
Quotes you view appear here for quick access.

XOMA Corporation Message Board

  • gfhammond1996 gfhammond1996 Nov 25, 2012 12:23 PM Flag

    Anyone know what the other two FDC candidates might be?

    The agreement includes the angiotensin converting enzyme (ACE) inhibitor perindopril, currently marketed under the trade name of ACEON®, and a portfolio of three fixed-dose combination product candidates where perindopril is combined with other active ingredient(s). The proprietary form of perindopril in each of the combination product candidates provides patent protection until 2023. The first product candidate XOMA elected to develop is a fixed-dose combination of perindopril arginine and amlodipine besylate.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
XOMA
3.415+0.025(+0.74%)May 22 4:00 PMEDT